These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 29069924)
1. Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer's toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function. Sathya S; Shanmuganathan B; Saranya S; Vaidevi S; Ruckmani K; Pandima Devi K Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1719-1730. PubMed ID: 29069924 [TBL] [Abstract][Full Text] [Related]
2. Phytol loaded PLGA nanoparticles regulate the expression of Alzheimer's related genes and neuronal apoptosis against amyloid-β induced toxicity in Neuro-2a cells and transgenic Caenorhabditis elegans. Sathya S; Shanmuganathan B; Balasubramaniam B; Balamurugan K; Devi KP Food Chem Toxicol; 2020 Feb; 136():110962. PubMed ID: 31734340 [TBL] [Abstract][Full Text] [Related]
3. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease. Huo X; Zhang Y; Jin X; Li Y; Zhang L J Photochem Photobiol B; 2019 Jan; 190():98-102. PubMed ID: 30504054 [TBL] [Abstract][Full Text] [Related]
4. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice. Jeon SG; Cha MY; Kim JI; Hwang TW; Kim KA; Kim TH; Song KC; Kim JJ; Moon M Nanomedicine; 2019 Apr; 17():297-307. PubMed ID: 30794963 [TBL] [Abstract][Full Text] [Related]
5. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747 [TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis in lung cancer cells through co-delivery of PLGA phytol/α-bisabolol nanoparticles. Kiruthiga C; Balan DJ; Prasath NH; Manikandakrishnan M; Jafni S; Prabhu NM; Pandian SK; Devi KP Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5131-5144. PubMed ID: 38240783 [TBL] [Abstract][Full Text] [Related]
7. Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of Aβ Bhatt PC; Verma A; Al-Abbasi FA; Anwar F; Kumar V; Panda BP Int J Nanomedicine; 2017; 12():8749-8768. PubMed ID: 29263666 [TBL] [Abstract][Full Text] [Related]
8. Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology. Wu Q; Karthivashan G; Nakhaei-Nejad M; Anand BG; Giuliani F; Kar S Int J Biol Macromol; 2022 Oct; 219():1180-1196. PubMed ID: 36030976 [TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of bee venom-loaded PLGA particles for sustained release. Park MH; Jun HS; Jeon JW; Park JK; Lee BJ; Suh GH; Park JS; Cho CW Pharm Dev Technol; 2018 Nov; 23(9):857-864. PubMed ID: 27881046 [TBL] [Abstract][Full Text] [Related]
10. Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells. Sokol MB; Nikolskaya ED; Yabbarov NG; Zenin VA; Faustova MR; Belov AV; Zhunina OA; Mollaev MD; Zabolotsky AI; Tereshchenko OG; Severin ES J Biomed Mater Res B Appl Biomater; 2019 May; 107(4):1150-1158. PubMed ID: 30281905 [TBL] [Abstract][Full Text] [Related]
11. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity. Xiong N; Dong XY; Zheng J; Liu FF; Sun Y ACS Appl Mater Interfaces; 2015 Mar; 7(10):5650-62. PubMed ID: 25700145 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease? Aalinkeel R; Kutscher HL; Singh A; Cwiklinski K; Khechen N; Schwartz SA; Prasad PN; Mahajan SD J Drug Target; 2018 Feb; 26(2):182-193. PubMed ID: 28697660 [TBL] [Abstract][Full Text] [Related]
15. Multiple-Coated PLGA Nanoparticles Loading Triptolide Attenuate Injury of a Cellular Model of Alzheimer's Disease. Jia L; Nie XQ; Ji HM; Yuan ZX; Li RS Biomed Res Int; 2021; 2021():8825640. PubMed ID: 33708996 [TBL] [Abstract][Full Text] [Related]
16. Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect. Anwer MK; Mohammad M; Iqbal M; Ansari MN; Ezzeldin E; Fatima F; Alshahrani SM; Aldawsari MF; Alalaiwe A; Alzahrani AA; Aldayel AM J Thromb Thrombolysis; 2020 Apr; 49(3):404-412. PubMed ID: 31898270 [TBL] [Abstract][Full Text] [Related]
17. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Cano A; Ettcheto M; Chang JH; Barroso E; Espina M; Kühne BA; Barenys M; Auladell C; Folch J; Souto EB; Camins A; Turowski P; García ML J Control Release; 2019 May; 301():62-75. PubMed ID: 30876953 [TBL] [Abstract][Full Text] [Related]
18. Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells. Roberts R; Smyth JW; Will J; Roberts P; Grek CL; Ghatnekar GS; Sheng Z; Gourdie RG; Lamouille S; Foster EJ Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110191. PubMed ID: 31923988 [TBL] [Abstract][Full Text] [Related]
19. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sousa F; Cruz A; Fonte P; Pinto IM; Neves-Petersen MT; Sarmento B Sci Rep; 2017 Jun; 7(1):3736. PubMed ID: 28623267 [TBL] [Abstract][Full Text] [Related]
20. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. Mathew A; Fukuda T; Nagaoka Y; Hasumura T; Morimoto H; Yoshida Y; Maekawa T; Venugopal K; Kumar DS PLoS One; 2012; 7(3):e32616. PubMed ID: 22403681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]